{"id":353,"date":"2018-09-28T13:13:31","date_gmt":"2018-09-28T11:13:31","guid":{"rendered":"https:\/\/cmt-awareness.com\/?page_id=353"},"modified":"2018-09-28T13:13:56","modified_gmt":"2018-09-28T11:13:56","slug":"bibliographie","status":"publish","type":"page","link":"https:\/\/cmt-awareness.com\/fr\/bibliographie\/","title":{"rendered":"Bibliographie"},"content":{"rendered":"<p>1: DiVincenzo C et al. The alle\/ic spectrum of Charcot-Marie-Tooth disease in over 17&rsquo;000 idividua\/s with neuropathy. Molecular Genetics &amp; Genomic Medicine. 2014:522-9.<\/p>\n<p>2: Shy ME et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-83.<\/p>\n<p>3: Bird TD. Charcot-Marie-Tooth Neuropathy Type 1. ln: Pagan RA, Adam MP, Ardinger HH et al. editors. GeneReviews\u00ae . Seattle (WA): University of Washington, Seattle; 1993-2015. 1998 Aug 31 [updated 2015 Mar 26].<\/p>\n<p>4: Brennan KM, Bai Y, Shy ME. Demye\/inating CMT&#8211;what&rsquo;s known, what&rsquo;s new and what&rsquo;s in store? Neurosci Lett. 2015;596:14-26.<\/p>\n<p>5: Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neural. 2011 ;69:22-33<\/p>\n<p>6: Grandis M, Shy ME. Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neural. 2005;7:23-31.<\/p>\n<p>7: Schr\u00f4der JM. Neuropathology of Charcot-Marie-Tooth and related disorders. Neuromolecular Med. 2006;8:23-42.<\/p>\n<p>8: Franssen H. Electrophysiology in demyelinating polyneuropathies. Expert Rev Neurother. 2008;8:417-31.<\/p>\n<p>9: Shy ME, Blake J, Krajewski K et al. Reliability and validity of the GMT neuropathy score as a measure of disability. Neuro\/ogy. 2005;64: 1209-14.<\/p>\n<p>10: Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overa\/1 Neuropathy Limitations Scale. J Neural Neurosurg Psychiatry. 2006;77:973-6.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>1: DiVincenzo C et al. The alle\/ic spectrum of Charcot-Marie-Tooth disease in over 17&rsquo;000 idividua\/s with neuropathy. Molecular Genetics &amp; Genomic Medicine. 2014:522-9. 2: Shy ME et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-83. 3: Bird TD. Charcot-Marie-Tooth Neuropathy Type 1. ln: Pagan RA, Adam MP, Ardinger HH et al. editors. GeneReviews\u00ae&hellip; <br \/> <a class=\"read-more\" href=\"https:\/\/cmt-awareness.com\/fr\/bibliographie\/\">Read more<\/a><\/p>\n","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-353","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/pages\/353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/comments?post=353"}],"version-history":[{"count":2,"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/pages\/353\/revisions"}],"predecessor-version":[{"id":355,"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/pages\/353\/revisions\/355"}],"wp:attachment":[{"href":"https:\/\/cmt-awareness.com\/fr\/wp-json\/wp\/v2\/media?parent=353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}